EUVIMEDEUVIMED entdecken
Crossref

Amiloride synergizes with EGFR PROTACs and inhibitors to overcome therapeutic resistance in NSCLC

Xiaojuan Qu, Hongyue Ou, Yifan Wu, Biao Jiang, Xiaoling Song

Bioorganic Chemistry · 2025

DOI: 10.1016/j.bioorg.2025.108641 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2025. Verfasst von Xiaojuan Qu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; School of Life Science and Technology, Shang…. Hauptthemen laut MEDLINE: Amiloride, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, ShanghaiTech University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for most cases. Among NSCLC patients, approximately 15-30 % harbor activating mutations in the Epidermal Growth Factor Receptor (EGFR), making them eligible for treatment with tyrosine kinase inhibitors (TKIs) like osimertinib, which has shown significant therapeutic benefits. However, acquired resistance to these therapies remains a major challenge in improving long-term clinical outcomes, underscoring the urgent need for novel strategies to address treatment resistance. In this study, we investigated the therapeutic potential of Amiloride (MK-870), a sodium channel inhibitor, as an adjuvant to EGFR-targeted therapies for NSCLC. Our findings demonstrate that MK-870 exhibits synergistic effects with EGFR PROTACs and small-molecule inhibitors, significantly enhancing antitumor activity in NSCLC cell lines. We identified α-ENaC (encoded by SCNN1A) as a key regulator of EGFR stability, with high α-ENaC expression correlating with reduced sensitivity to EGFR. MK-870 achieves dual downregulation of EGFR at both transcriptional and protein levels via targeted inhibition of sodium channel proteins. Furthermore, MK-870 enhances lysosomal activity in multiple NSCLC cell lines and EGFR-overexpressing NIH/3 T3 cells-a phenomenon potentially linked to its inhibition of sodium‑hydrogen exchanger (NHE) to promote cellular acidification. Mechanistically, the resultant acidification promotes apoptosis while simultaneously enhancing lysosome-mediated degradation of EGFR proteins by PROTAC molecules. Collectively, MK-870 synergizes with EGFR-targeting agents through coordinated modulation of sodium channel proteins and NHE-mediated pH homeostasis. These novel insights highlight MK-870 as a promising adjuvant for overcoming EGFR-targeted therapeutic resistance in NSCLC, offering a new avenue for improving patient outcomes in this challenging disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmilorideAntineoplastic AgentsCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsProtein Kinase InhibitorsHumansCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorDrug SynergismErbB ReceptorsMolecular StructureProteolysis Targeting ChimeraStructure-Activity Relationship

Stichwörter der Autor:innen

AmilorideEGFR PROTACsTargeted protein degradationTherapeutic resistanceα-ENaC

Substanzen

AmilorideAntineoplastic AgentsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsProteolysis Targeting ChimeraMK-870

Autor:innen und Institutionen

  • Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China.
  • Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; CAS Key Laboratory of Synthetic Chemistry of Natural Substances, Shanghai Institute of Organic Chemistry, Chinese…
  • Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China. Electronic address: songxl@shanghaitech.edu.cn.

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • ShanghaiTech University
  • National Natural Science Foundation of China

Zitieren

APA

Qu, X., Ou, H., Wu, Y., Jiang, B., & Song, X. (2025). Amiloride synergizes with EGFR PROTACs and inhibitors to overcome therapeutic resistance in NSCLC. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.108641

Vancouver

Qu X, Ou H, Wu Y, Jiang B, Song X. Amiloride synergizes with EGFR PROTACs and inhibitors to overcome therapeutic resistance in NSCLC. Bioorganic Chemistry. 2025. doi:10.1016/j.bioorg.2025.108641

BibTeX
@article{Qu2025,
  author = {Qu, Xiaojuan and Ou, Hongyue and Wu, Yifan and Jiang, Biao and Song, Xiaoling},
  title = {Amiloride synergizes with EGFR PROTACs and inhibitors to overcome therapeutic resistance in NSCLC},
  journal = {Bioorganic Chemistry},
  year = {2025},
  doi = {10.1016/j.bioorg.2025.108641}
}
Kostenlos starten →